Skip to content

Advertisement

BMC Cancer

Experimental therapeutics and drug development

This section covers all aspects of preclinical investigations on therapeutic agents. It welcomes submissions concerning anti-cancer drug discovery and development, and targeted therapies.

Previous Page Page 3 of 19 Next Page
  1. Content type: Research article

    The aim of this study was to determine whether checkpoint kinase 1 inihibitor (CHK1), LY2603618, and gemcitabine prolong overall survival (OS) compared to gemcitabine alone in patients with unresectable pancre...

    Authors: Berta Laquente, Jose Lopez-Martin, Donald Richards, Gerald Illerhaus, David Z. Chang, George Kim, Philip Stella, Dirk Richel, Cezary Szcylik, Stefano Cascinu, G. L. Frassineti, Tudor Ciuleanu, Karla Hurt, Scott Hynes, Ji Lin, Aimee Bence Lin…

    Citation: BMC Cancer 2017 17:137

    Published on:

  2. Content type: Research article

    Cisplatin (DDP)-based chemotherapy is the common first-line therapy for lung cancer. However, their efficacy is often limited by primary drug resistance and/or acquired drug resistance. The aim of this study w...

    Authors: Lin Shi, Zhaozhong Xu, Gang Wu, Xiaoting Chen, Yuanyuan Huang, Yanjing Wang, Weiqiang Jiang and Bin Ke

    Citation: BMC Cancer 2017 17:138

    Published on:

  3. Content type: Research article

    Bacterial toxins have evolved to an effective therapeutic option for cancer therapy. The Clostridium perfringens enterotoxin (CPE) is a pore-forming toxin with selective cytotoxicity. The transmembrane tight junc...

    Authors: Jessica Pahle, Lutz Menzel, Nicole Niesler, Dennis Kobelt, Jutta Aumann, Maria Rivera and Wolfgang Walther

    Citation: BMC Cancer 2017 17:129

    Published on:

  4. Content type: Research article

    Antiangiogenic therapies are considered promising for the treatment of glioblastoma (GB). The non-collagenous C-terminal globular NC1 domain of type VIII collagen a1 chain, Vastatin, is an endogenous antiangio...

    Authors: Yi Li, Jun Li, Yat Ming Woo, Zan Shen, Hong Yao, Yijun Cai, Marie Chia-mi Lin and Wai Sang Poon

    Citation: BMC Cancer 2017 17:126

    Published on:

  5. Content type: Research article

    Photodynamic therapy (PDT) has proven to be a promising alternative to current cancer treatments, especially if combined with conventional approaches. The technique is based on the administration of a non-toxi...

    Authors: Laura Marise de Freitas, Rodolfo Bortolozo Serafim, Juliana Ferreira de Sousa, Thaís Fernanda Moreira, Cláudia Tavares dos Santos, Amanda Martins Baviera, Valeria Valente, Christiane Pienna Soares and Carla Raquel Fontana

    Citation: BMC Cancer 2017 17:123

    Published on:

  6. Content type: Research article

    Glioblastoma Multiforme (GBM) is the most common and lethal form of primary brain tumor in adults. Following standard treatment of surgery, radiation and chemotherapy, patients are expected to survive 12–14 mo...

    Authors: Zachary C. Gersey, Gregor A. Rodriguez, Eric Barbarite, Anthony Sanchez, Winston M. Walters, Kelechi C. Ohaeto, Ricardo J. Komotar and Regina M. Graham

    Citation: BMC Cancer 2017 17:99

    Published on:

  7. Content type: Research article

    Advanced urothelial carcinomas represent a considerable clinical challenge as they are difficult to treat. Platinum-based combination regimens obtain response rates ranging from 40 to 70% in first-line therapy...

    Authors: Sergey A. Dyshlovoy, Ramin Madanchi, Jessica Hauschild, Katharina Otte, Winfried H. Alsdorf, Udo Schumacher, Vladimir I. Kalinin, Alexandra S. Silchenko, Sergey A. Avilov, Friedemann Honecker, Valentin A. Stonik, Carsten Bokemeyer and Gunhild von Amsberg

    Citation: BMC Cancer 2017 17:93

    Published on:

  8. Content type: Research article

    Concurrent cisplatin radiotherapy (CCRT) is a current standard-of-care for locally advanced head and neck squamous cell carcinoma (HNSCC). However, CCRT is frequently ineffective in patients with advanced dise...

    Authors: Martin McLaughlin, Holly E. Barker, Aadil A. Khan, Malin Pedersen, Magnus Dillon, David C. Mansfield, Radhika Patel, Joan N. Kyula, Shreerang A. Bhide, Kate L. Newbold, Christopher M. Nutting and Kevin J. Harrington

    Citation: BMC Cancer 2017 17:86

    Published on:

  9. Content type: Research article

    Osteosarcoma (OS) is the most common primary bone tumor in both humans and dogs and is the second leading cause of cancer related deaths in children and young adults. Limb sparing surgery along with chemothera...

    Authors: Sridhar Murahari, Aimee L. Jalkanen, Samuel K. Kulp, Ching-Shih Chen, Jaime F. Modiano, Cheryl A. London and William C. Kisseberth

    Citation: BMC Cancer 2017 17:67

    Published on:

  10. Content type: Research article

    Despite considerable efforts by scientific research, pancreatic cancer is the fourth leading cause of cancer related mortalities. Sigma-2 receptors, which are overexpressed in several tumors, represent promisi...

    Authors: Maria Laura Pati, John R. Hornick, Mauro Niso, Francesco Berardi, Dirk Spitzer, Carmen Abate and William Hawkins

    Citation: BMC Cancer 2017 17:51

    Published on:

  11. Content type: Research article

    Combination drug therapy appears a promising approach to overcome drug resistance and reduce drug-related toxicities in ovarian cancer treatments. In this in vitro study, we evaluated the antitumor efficacy of...

    Authors: Vijayalakshmi N. Ayyagari, Tsung-han Jeff Hsieh, Paula L. Diaz-Sylvester and Laurent Brard

    Citation: BMC Cancer 2017 17:49

    Published on:

  12. Content type: Research article

    Norcantharidin (NCTD) is a Chinese FDA approved, chemically synthesized drug for cancer treatment. The effect of NCTD on signaling proteins of EGFR and c-Met was systematically elucidated in current study.

    Authors: Peiju Qiu, Siwen Wang, Ming Liu, He Ma, Xuan Zeng, Meng Zhang, Lingling Xu, Yidi Cui, Huixin Xu, Yang Tang, Yanli He and Lijuan Zhang

    Citation: BMC Cancer 2017 17:55

    Published on:

  13. Content type: Research article

    Metabolic toxicities of mTOR inhibitors (mTORi) are well characterized. The purpose of the study was to investigate the relationship between these metabolic toxicities and mTORi efficacy.

    Authors: M. Jebali, R. Elaidi, M. Brizard, J. Fouque, C. Takouchop, B. Sabatier, S. Oudard and J. Medioni

    Citation: BMC Cancer 2017 17:27

    Published on:

  14. Content type: Research article

    In endemic area, nasopharyngeal carcinoma (NPC) tumor cells harbor EBV latent infection and expresses viral antigens such as EBNA1, LMP1 and LMP2. In this study, we established a NPC-mimicry animal model and a...

    Authors: Mei-Chun Lin, Yong-Chong Lin, Syue-Ting Chen, Tai-Horng Young and Pei-Jen Lou

    Citation: BMC Cancer 2017 17:18

    Published on:

  15. Content type: Research article

    Colorectal cancer (CRC) is the 3rd most common type of cancer worldwide. New anti-cancer agents are needed for treating late stage colorectal cancer as most of the deaths occur due to cancer metastasis. A recentl...

    Authors: Khayal Al-Khayal, Ahmed Alafeefy, Mansoor-Ali Vaali-Mohammed, Amer Mahmood, Ahmed Zubaidi, Omar Al-Obeed, Zahid Khan, Maha Abdulla and Rehan Ahmad

    Citation: BMC Cancer 2017 17:4

    Published on:

  16. Content type: Research article

    Colorectal cancer is the second most common cause of cancer deaths for both men and women, and the third most common cause of cancer in the U.S. Toxicity of current chemotherapeutic agents for colorectal cance...

    Authors: Jeffrey Wimsatt, Meghan Villers, Laurel Thomas, Stacey Kamarec, Caitlin Montgomery, Leo W. Y. Yeung, Yanqing Hu and Kim Innes

    Citation: BMC Cancer 2016 16:942

    Published on:

  17. Content type: Research article

    The study was designed to develop a platform to verify whether the extract of herbs combined with chemotherapy drugs play a synergistic role in anti-tumor effects, and to provide experimental evidence and theo...

    Authors: Jun Xie, Jia-Hui Liu, Heng Liu, Xiao-Zhong Liao, Yuling Chen, Mei-Gui Lin, Yue-Yu Gu, Tao-Li Liu, Dong-Mei Wang, Hui Ge and Sui-Lin Mo

    Citation: BMC Cancer 2016 16:899

    Published on:

  18. Content type: Research article

    The polyether antibiotic Salinomycin (Sal) is regarded as an inhibitor of cancer stem cells. Its effectiveness on human colorectal cancer (CRC) cells in vitro has been demonstrated before. The aim of this stud...

    Authors: Johannes Klose, Jana Eissele, Claudia Volz, Steffen Schmitt, Alina Ritter, Shen Ying, Thomas Schmidt, Ulrike Heger, Martin Schneider and Alexis Ulrich

    Citation: BMC Cancer 2016 16:896

    Published on:

  19. Content type: Research article

    Neuroblastoma (NB) is a frequent pediatric tumor characterized by a poor prognosis where a majority of tumors progress despite intensive multimodality treatments. Autophagy, a self-degradative process in cells...

    Authors: Assila Belounis, Carine Nyalendo, Roxane Le Gall, Tina V. Imbriglio, Mohamed Mahma, Pierre Teira, Mona Beaunoyer, Sonia Cournoyer, Elie Haddad, Gilles Vassal and Hervé Sartelet

    Citation: BMC Cancer 2016 16:891

    Published on:

  20. Content type: Research article

    Endostar is a new endogenous angiogenic inhibitor with implicated anti-tumor activity. This study was to investigate whether thoracic perfusion of Endostar could be used to control malignant pleural effusions ...

    Authors: Rong Biaoxue, Cai Xiguang, Liu Hua, Gao Wenlong and Yang Shuanying

    Citation: BMC Cancer 2016 16:888

    Published on:

Previous Page Page 3 of 19 Next Page